Cormorant Asset Management

About

Portfolio · 2

Fore Biotherapeutics

Precision Oncology Treatments

2 rounds $132.0M committed Latest: 2023-08

Chemomab Therapeutics

Innovative Treatments for Patients with Fibro-Inflammatory-Related Diseases

Led ★ 1 round $45.5M committed Latest: 2021-03

Investment activity

1 portfolio exit on record.

Q&A

What is Cormorant Asset Management's primary investment focus?

Cormorant Asset Management specializes in healthcare and life sciences, investing in biotechnology, pharmaceutical, and healthcare technology companies across private and public markets.

When was Cormorant Asset Management founded?

Cormorant Asset Management was founded in 2013.

Which notable companies are in Cormorant Asset Management's portfolio?

Cormorant Asset Management's portfolio includes Chemomab Therapeutics.

Has Cormorant Asset Management had any exits?

Yes, Cormorant Asset Management had an exit in March 2021 with Chemomab Therapeutics, which completed a reverse merger with Anchiano Therapeutics and began trading on NASDAQ.

Who are the key individuals at Cormorant Asset Management?

Bihua Chen is the Founder & CEO, and Raymond Kelleher serves as a Managing Director at Cormorant Asset Management.

What is Cormorant Asset Management's geographic focus for investments?

Cormorant Asset Management is headquartered in Boston, United States, and its portfolio companies include Chemomab Therapeutics and Fore Biotherapeutics.

What is the typical investment stage for Cormorant Asset Management?

Cormorant Asset Management invests in various stages, including C Round, D Round, E Round, and PIPE rounds, with a focus on growth-stage businesses.